Salmeterol/fluticasone propionate - Neothetics

Drug Profile

Salmeterol/fluticasone propionate - Neothetics

Alternative Names: Fluticasone propionate/salmeterol - Neothetics; LIPO-102; Salmeterol xinafoate/fluticasone propionate - Lithera; Salmeterol xinafoate/fluticasone propionate - Neothetics

Latest Information Update: 28 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lithera
  • Developer Neothetics
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eye disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Exophthalmos
  • Discontinued Subcutaneous fat disorders

Most Recent Events

  • 31 Dec 2016 Neothetics has patent protection for Salmeterol/fluticasone propionate in USA and other countries
  • 31 Mar 2015 Phase II development is ongoing in Exophthalmos in Australia and New Zealand
  • 31 Mar 2015 Discontinued - Phase-II for Subcutaneous fat disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top